Year: 2024

BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration...

GUANGZHOU, China, Nov. 13, 2024 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Urban Air Mobility (“UAM”) technology platform company, today announced a significant breakthrough in the development of high-energy solid-state battery technology, in collaboration with the Low-Altitude Economy Battery Research Institute of the Hefei International Advanced Technology Application Promotion Center and Shenzhen Inx Energy Technology Co., Ltd. (“Inx”). Equipped with this solid-state battery, EH216-S completed a continuous 48 minutes and 10 seconds flight test, which is applicable to different flight requirements and significantly improves the flight endurance by 60%-90%. Notably, this marks a milestone as the first pilotless passenger-carrying electric vertical takeoff and landing...

FOR RELEASE IN SWITZERLAND – THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN. Not for release, publication or distribution, in whole or in part, directly or indirectly, in the United States of America, Canada, Japan or Australia or any other jurisdiction in which the release, publication or distribution would be unlawful. Zurich, 13 November 2024 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 Listing Rules: GAM Holding AG announces rights take-up and number of shares sold in its rights offering GAM Holding AG (“GAM”) announces that in its rights offering and placement of 904,464,247 newly issued registered shares (the “Offered Shares“) (the “Offering“), 42% of...

To whom It may concern,  Please find enclosed Alstom’s presentation for its first half results of fiscal year 2024/25. Best Regards, Alstom Investor Relations TeamAttachmentPresentation H1 2024-25 Final

  Alstom’s first half 2024/25: good commercial performance, confirmation of FY 2024/25 outlookH1 2024/25 highlights:Book-to-bill ratio at 1.25 and organic sales up 5.6%1 aEBIT2 of €515 million, up 18%, i.e. margin of 5.9% Free Cash Flow2 at €(138) million benefiting from favourable downpayments phasing   Net financial debt at €(927) million down from €(2,994) million after deleveraging plan executionFY 2024/25 outlookBook-to-bill above 1 and sales organic growth around 5% aEBIT margin around 6.5% Free Cash Flow within the range €300 million to €500 million13 November 2024 – In the first half of fiscal year 2024/25 (from 1st April to 30 September 2024), Alstom booked €10.9 billion of orders. The Group sales reached €8.8 billion, resulting in a book-to-bill ratio at 1.25. The backlog is now €94.4 billion, providing strong...

Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Valneva obtained an exclusive worldwide license from LimmaTech1. In the CHIM study S4V03 (Identifier: NCT06615375), S4V2 will be tested for safety and preliminary efficacy in approximately 120 healthy Shigella-naïve participants aged 18 to 50 years at three sites in the United States. The study, sponsored and conducted by...

ASHEVILLE, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“Company”), the holding company of HomeTrust Bank (“Bank”, “HomeTrust” or “HTB”), today announced that the Bank has ranked 156 in the Top 200 of Newsweek Magazine’s America’s Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI). In addition, HTB has also been recognized by American Banker as a 2024 Best Bank to Work For. Within the Most Loved Workplace awards, HomeTrust also achieved a top ranking Most Loved Workplace in six categories: Most Loved Workplaces for Wellness, Most Loved Workplace for Veterans, Most Loved Workplace for Parents & Caregivers, Most Loved CEO at Most Loved Workplaces, Most Loved Workplaces for Volunteering, and Most Loved Workplaces for Women. Each of...

Sanoma Corporation, Stock exchange release, 13 November 2024 at 18:30 EET SANOMA CORPORATION: ACQUISITION OF OWN SHARES 13 November 2024 Nasdaq Helsinki Ltd:Date 13 November 2024  Exchange transaction Buy  Share class SANOMA  Amount 8,200  Average price/share, EUR 7.2733  Highest price/share, EUR 7.3200  Lowest price/share, EUR 7.2400  Total cost, EUR 59,641.06       The company holds a total of 149,197 of its own shares (SANOMA) including the shares acquired on 13 November 2024. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Sanoma Corporation Skandinaviska Enskilda Banken AB (publ) Helsinki branch Antti Salakka    Janne Tiihonen Additional information Kaisa Uurasmaa, Head of Investor Relations and...

KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 13 NOVEMBER 2024 AT 6.30 PM (EET)          KALMAR CORPORATION: SHARE REPURCHASE 13.11.2024     In the Helsinki Stock Exchange         Trade date 13.11.2024  Bourse trade Buy  Share KALMAR  Amount 7,000 SharesAverage price/ share 31.6743 EURTotal cost 221,720.10 EUR          Kalmar Corporation now holds a total of 67 000 sharesincluding the shares repurchased on 13.11.2024          On behalf of Kalmar Corporation         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       For further information, please contact:  Sakari Ahdekivi, CFO, tel. +358 50 400 3557  Carina Geber-Teir, SVP, IR, Marketing & Communications, tel. +358 40 502 4697     www.kalmarglobal.com    AttachmentKalmar_13.11_trades ...

Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack conditions.   Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without any handling problem. Study underscores ZENEO® Midazolam’s usability in extreme, high-risk scenarios.Dijon, France, November 13, 2024 — Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, has successfully completed a human factors study under extreme stress conditions. The test, designed...